Argenx’s investigational therapy, subcutaneous efgartigimod alfa, has been granted Promising Innovative Medicine (PIM) status ...
A new treatment for asthma and COPD attacks could revolutionise patient care, scientists say. An injection given during ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback